Average Co-Inventor Count = 4.05
ph-index = 22
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Incyte Corporation (88 from 651 patents)
2. Incyte Holdings Corporation (46 from 146 patents)
3. Bristol-myers Squibb Pharma Company (4 from 234 patents)
4. Bristol-myers Squibb Compnay (2 from 3,657 patents)
5. Incyte Corportion (1 from 1 patent)
95 patents:
1. 12247020 - Bipyrazole derivatives as JAK inhibitors
2. 12201636 - Heterocyclylamines as PI3K inhibitors
3. 12152033 - Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders
4. 12084449 - Imidazotriazines and imidazopyrimidines as kinase inhibitors
5. 11999751 - Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
6. 11905275 - Bipyrazole derivatives as JAK inhibitors
7. 11851442 - Tricyclic fused thiophene derivatives as JAK inhibitors
8. 11819505 - Heterocyclylamines as PI3K inhibitors
9. 11591318 - Bipyrazole derivatives as JAK inhibitors
10. 11591338 - Pyrrolotriazine compounds as TAM inhibitors
11. 11433071 - Heterocyclylamines as PI3K inhibitors
12. 11401280 - Pyrimidinones as PI3K inhibitors
13. 11261191 - Imidazotriaines and imidazopyrimidines as kinase inhibitors
14. 11229631 - Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
15. 11161855 - Tricyclic fused thiophene derivatives as JAK inhibitors